Glp-1 weight loss denied due to quantity / dose limits by Cigna?

Cigna's commercial coverage policy IP0206 targets liraglutide (Saxenda, generic), Wegovy, and Zepbound for chronic weight management and requires prior authorization. For adult initial therapy, the patient must have a BMI ≥ 30 kg/m² (obesity), or a BMI exceeding 30 or a comorbid condition, such as diabetes or hypertension, with a BMI over 27 ; recognized weight-related comorbidities include hypertension, Type 2 diabetes, dyslipidemia (high cholesterol), obstructive sleep apnea, or cardiovascular disease . Pediatric criteria require BMI ≥ 95th percentile for age and sex . Initial approval durations differ by product: approve for 4 months for Saxenda initial therapy , approve for 7 months of Wegovy initial therapy , and approve for 8 months of Zepbound initial therapy , with 1-year reauthorization contingent on continued therapy and demonstrated weight-loss response. For continuation, response to pharmacologic therapy should be assessed after 3 months on a therapeutic dose; if treatment has not resulted in ≥ 5% weight loss, longer-term efficacy will not likely be sufficient and a change is recommended; individuals with weight reduction ≥ 5% should continue with their current treatment . Additional MACE-reduction coverage exists for Wegovy in adults with established cardiovascular disease with overweight or obesity (e.g., prior MI, stroke, or symptomatic peripheral arterial disease), and Wegovy for MASH/NASH must be prescribed by or in consultation with a physician who specializes in the condition being treated ; Wegovy is not indicated in patients with cirrhotic (F4) MASH . Combined use with another GLP-1 or GLP-1/GIP agonist is not approved, and quantity limits restrict claims to one GLP-1 agonist at a time.

- For BMI/comorbidity denials: cite FDA labeling and AACE/Obesity Society guidelines supporting pharmacotherapy at BMI ≥ 30 or ≥ 27 with comorbidities; submit chart documentation of measured BMI and ICD-10-coded comorbidity (HTN, T2DM E11, OSA G47.33, dyslipidemia E78). - For lifestyle-modification denials: provide documented participation in a structured reduced-calorie diet, physical activity, and behavioral counseling, consistent with the policy's own framework that treatment is to address complications and diseases, not solely to reduce BMI, and the choice of pharmacotherapy is based on obesity-related comorbidities ; reference the STEP and SURMOUNT trial protocols which paired drug therapy with lifestyle intervention. - For inadequate-response denials at reauthorization: provide weighed clinic measurements showing ≥ 5% loss; note the policy itself acknowledges patients who achieve ≥ 15% weight loss (the average observed with Wegovy and Zepbound) achieve a response that predictably prevents or improves a wide range of complications — supported by STEP 1 (Wilding NEJM 2021) and SURMOUNT-1 (Jastreboff NEJM 2022). - For cardiovascular indication denials on Wegovy: cite the SELECT trial (Lincoff NEJM 2023) showing 20% MACE reduction; per policy, established cardiovascular disease with overweight or obesity is approvable with documentation of prior MI, stroke, or symptomatic PAD. - For OSA-related denials on Zepbound: cite SURMOUNT-OSA results referenced in the policy itself — in both trials, Zepbound was superior to placebo for the primary endpoint; in Trial 1, the change in AHI at Week 52 with Zepbound was superior to placebo (-25.3 events/hour vs. -5.3 events/hour) ; align with ATS 2018 OSA weight-management guideline recommending anti-obesity pharmacotherapy in BMI ≥ 27 patients. - For MASH/NASH denials on Wegovy: provide specialist (hepatology/GI) attestation and documentation of stage F2 or F3 fibrosis confirmed by liver biopsy within 3 years, vibration-controlled elastography (VCTE), or MRE ; cite ESSENCE trial results. - For "not medically necessary" denials: reference ADA Standards of Care 2024 and AACE 2023 endorsing GLP-1 RAs and GLP-1/GIP agonists for chronic weight management with cardiometabolic comorbidities, and the AHA 2021 Scientific Statement on obesity and CVD risk.

## Why Cigna Denied This GLP-1 for Weight Loss: Quantity Limits

Cigna's quantity-limit denial means the prescription as written exceeds the quantity, days' supply, or dosing frequency that Cigna's formulary allows for GLP-1 medications used for weight management. This type of denial is common with injectable medications that follow dose-escalation protocols, because the titration schedule your prescriber ordered may not align with the default quantity Cigna auto-approves.

## Why It Is Appealable

Quantity limits are set administratively and do not always account for individual clinical need. If your prescriber determined that the prescribed quantity — including any titration doses — is medically necessary based on your clinical profile, Cigna is required by your plan's terms and applicable law to consider an exception. A well-documented appeal explaining why the standard quantity is clinically insufficient for your situation is a recognized path to coverage.

## Federal Appeal Framework

• Internal appeal (ACA §2719 / ERISA §503): All adverse benefit determinations, including quantity-limit denials, are subject to a full and fair internal review. File your appeal in writing within the deadline shown on the denial notice.
• Expedited review: Available if the standard timeline would seriously harm your health — for example, if interrupting a titration sequence would cause clinically significant setback.
• External review: After internal appeal exhaustion, you may seek independent external review under ACA §2719 within approximately four months of the denial notice.

## Documentation to Gather

1. Prescriber's clinical rationale: A letter from your prescribing physician explaining the specific dose-escalation schedule prescribed, why it reflects the FDA-approved titration protocol for this drug, and why any deviation would be clinically inappropriate for you. 2. FDA-approved prescribing label: The current prescribing information for the specific GLP-1 medication. Highlight the section describing the recommended titration schedule, which supports why the prescribed quantity is consistent with standard of care. 3. Clinical records: Chart notes documenting your weight-management history, your response to current therapy, and any clinical factors that make the prescribed quantity necessary. 4. Cigna's quantity-limit policy: Download Cigna's published formulary or medical policy document specifying the quantity limit applied to your claim. Understanding the exact limit lets you address it precisely. 5. Prior treatment history: Documentation of earlier weight-management interventions and their outcomes, contextualizing why adequate dosing of this agent matters now.

## Criteria-Mapping Structure

In your appeal letter, list the quantity limit Cigna applied (as stated in the denial) alongside the quantity prescribed and the FDA-labeled titration schedule. For each step in the titration sequence, cite the page in the prescribing label that describes it. Then attach your prescriber's clinical letter confirming that the prescribed quantity conforms to the label and is individually necessary. This structure makes it straightforward for Cigna's reviewer to verify that the quantity aligns with the approved treatment protocol.